Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02213263 · ClinicalTrials.gov registry record · Phase 3

A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)

A Phase 3 study of Follicular Lymphoma, sponsored by Pfizer.

Completed
Registry status
Phase 3
Development phase
394
Enrollment target
20
Study locations

NCT02213263: Completed Phase 3 study of Follicular Lymphoma, sponsored by Pfizer.

NCT02213263 is a Phase 3 study of Follicular Lymphoma that has completed, run by Pfizer. The registered enrollment target is 394 participants, above the 131-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (201% higher). The trial reports 20 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02213263, a Phase 3 study of Follicular Lymphoma, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 3
Development phase
394 participants
Enrollment target
20
Study locations

Study Summary

This study will compare the safety and effectiveness of PF-05280586 versus rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma. The primary hypothesis to be tested in this study is that the effectiveness of PF-05280586, as measured by the Overall Response Rate, is similar to that of rituximab-EU.

Primary Outcome

ORR was defined as the percentage of participants who achieved complete response (CR) or partial response (PR) in accordance with the revised response criteria for malignant lymphoma (Cheson 2007). CR was defined as disappearance of all evidence of disease. PR was defined as regression of measureable disease and no new sites.

Conditions Studied

Follicular Lymphoma

Interventions

  • BIOLOGICAL MabThera®
  • BIOLOGICAL PF-05280586

Study Locations (20)

California

  • Pacific Cancer Medical Center, Inc. - Anaheim
  • The Oncology Institute of Hope and Innovation - Anaheim
  • Compassionate Care Research Group, Inc., at Compassionate Cancer Care Medical Group, Inc. - Corona
  • The Oncology Institute of Hope and Innovation - Downey
  • Compassionate Care Research Group, Inc., at Compassionate Cancer Care Medical Group, Inc. - Fountain Valley
  • Global Cancer Research Institute (GCRI), Inc - Gilroy
  • Saint Louise Regional Hospital Radiology Department (Radiology Only) - Gilroy
  • South Valley Imaging Center (Imaging Only) - Gilroy
  • Los Angeles Hematology Oncology Medical Group - Glendale
  • The Oncology Institute of Hope and Innovation - Glendale
  • Los Angeles Hematology Oncology Medical Group - Glendale
  • The Oncology Institute of Hope and Innovation - Long Beach
  • Los Angeles Hematology Oncology Medical Group - Los Angeles
  • Los Angeles Hematology Oncology Medical Group - Los Angeles
  • The Oncology Institute of Hope and Innovation - Lynwood
  • The Oncology Institute of Hope and Innovation - Montebello
  • Comprehensive Cancer Center at Desert Regional Medical Center - Palm Springs
  • Torrance Health Association DBA, Torrance Memorial Physician, Network/Cancer Care Associates - Redondo Beach
  • Compassionate Care Research Group, Inc., at Compassionate Cancer Care Medical Group, Inc. - Riverside
  • Global Cancer Research Institute, Inc. - San Jose

Trial Details

FieldValue
Enrollment Target 394 participants
Start Date 2014-09-30
Est. Completion 2018-04-19
Phase Phase 3
Pfizer

1,845 total trials

What the finished NCT02213263 record still lists

NCT02213263 is an interventional study that assigns participants to a tested intervention. The registered 394 participants enrollment target is mid-sized for trials with a published cap, above the 131-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (201% higher).

The record links to 1 condition, with Follicular Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which MabThera® is the first listed.

NCT02213263 names 20 study sites across 1 states, led by California.

Frequently Asked Questions

What is clinical trial NCT02213263 about?

NCT02213263 is a clinical study titled "A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)". This study will compare the safety and effectiveness of PF-05280586 versus rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma. The primary hypothesis to be tested in this study is that the effectiveness of PF-05280586, as measured by the Overall Response Rate, is simil...

What is the current status of trial NCT02213263?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 394 participants. The study started on 2014-09-30. Estimated completion is 2018-04-19.

What conditions does trial NCT02213263 study?

This clinical trial studies the following conditions: Follicular Lymphoma.

What interventions are being tested in trial NCT02213263?

The interventions under investigation include: MabThera® (BIOLOGICAL), PF-05280586 (BIOLOGICAL).

Who is sponsoring clinical trial NCT02213263?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02213263 being conducted?

This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Follicular Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02213263's enrollment target sits among peer trials

394 9th of 89 higher than 81 of 89 other Follicular Lymphoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Follicular Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06657924 · 394 participants · Phase 2

    Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery

  • NCT07225660 · 394 participants · NA

    Hormonal Optimization: Late vs. Immediate Start After Discontinuation of Oral Contraceptives in Assisted Reproductive technologY (HOLIDAY)

  • NCT07207369 · 395 participants · Phase 3

    A Study to Assess the Safety and Effectiveness of ELAPR002f Injectable Gel in Adult Participants With Atrophic Acne Scars

  • NCT05640999 · 393 participants · Phase 2

    Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT02213263, the US trial registry maintained by the National Library of Medicine. NCT02213263 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.